Independent Retatrutide Intelligence

Founded by healthcare entrepreneur and author AJ Pakpour, TryTrutide is an independent educational platform dedicated to tracking retatrutide research, clinical evidence, regulation and emerging metabolic medicine.

What TryTrutide Is

TryTrutide is an independent educational and research platform focused specifically on retatrutide — the investigational triple agonist (GLP-1R / GIPR / GcgR) developed by Eli Lilly. We track published clinical evidence, trial data, regulatory developments, safety information, and emerging community discussions in one place.

Why TryTrutide Exists

Retatrutide is generating enormous interest among patients, clinicians, researchers, weight-loss communities, online forums, and emerging-medicine markets. The goal of TryTrutide is to separate published evidence, clinical-trial findings, regulatory facts, emerging research, internet claims, anecdotes, and unsupported speculation — and label each clearly.

Our Mission

Make retatrutide research, safety information, clinical-trial data, regulatory developments, and emerging conversations easier to understand. The platform is evidence-first, transparent, and regularly updated.

Independence

TryTrutide is not affiliated with, endorsed by, or sponsored by Eli Lilly, the FDA, ClinicalTrials.gov, or any academic institution. We cite these sources because they are authoritative — not because they endorse us. Editorial content distinguishes factual reporting, scientific interpretation, commentary, and medical review.

Current Status of Retatrutide

Retatrutide remains investigational and is not currently FDA approved. It is not commercially available. All information on this platform is for educational purposes only and does not constitute medical advice.

About the Founder

Founded by healthcare entrepreneur and author AJ Pakpour, TryTrutide brings together clinical-business analysis, healthcare publishing, and emerging-medicine research into a single independent platform.